AI assistant
Actinium Pharmaceuticals, Inc. — Director's Dealing 2017
May 17, 2017
34570_dirs_2017-05-17_c35e4ba8-8fe1-472c-b893-ca3ca1718ca8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2017-05-15
Reporting Person: O'Loughlin Steve (VP, Finance and Corporate Dev.)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options to purchase common stock | $1.79 | 2025-10-01 | Common Stock (100000) | Direct | |
| Options to purchase common stock | $1.99 | 2026-04-14 | Common Stock (50000) | Direct | |
| Options to purchase common stock | $1.39 | 2027-03-14 | Common Stock (100000) | Direct |
Footnotes
F1: A total of 28% of the options will vest one year from the grant date, and the remaining 72% shall vest in equal increments of 2% per month of the initial option grant over the following three year period.
F2: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.
F3: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 25,000 options are subject to cancellation based on the obtainment of certain milestones.